Dolcetti R, Zancai P, De Re V, Gloghini A, Bigoni B, Pivetta B, De Vita S, Carbone A, Boiocchi M
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy.
Blood. 1997 Mar 1;89(5):1723-31.
Six Epstein-Barr virus (EBV)-related lymphoproliferative disorders were investigated to verify whether the EBV strain harbored by neoplastic cells had the same EBNA-2 and latent membrane protein-1 (LMP-1) DNA sequences of the virus carried by normal lymphocytes of the same patients. Within each case, the analysis of neoplastic lymph nodes, reactive lymphadenopathies, and/or EBV+ spontaneous lymphoblastoid cell lines gave concordant results with respect to type-specific EBNA-2 region and LMP-1 gene. In particular, five cases showed the same deletion in the 3' end of the LMP-1 gene in both normal and neoplastic cells. We also determined the prevalence of LMP-1 deletions in a large series of normal peripheral blood mononucleated cells (PBMCs) from Italian individuals. The analysis showed that 50% (9 of 18) of PBMCs from human immunodeficiency virus (HIV)-seronegative donors carried a 30-bp deletion in the C-terminal portion of the LMP-1 gene, whereas a nondeleted fragment was amplified in about 44% (8 of 18) of the cases. Only one sample (5.6%) showed the amplification of a full-length LMP-1 band together with a deleted fragment. Similarly, PBMCs from HIV-infected patients showed an almost equivalent prevalence of full-length (17 of 37, 46%) and deleted (16 of 37, 43.2%) LMP-1 fragments, whereas about 11% of samples (4 of 37) showed evidence of double infections. Of note, deletions in the LMP-1 gene were detected with similar prevalence values in EBV+ Hodgkin's disease (HD) (13 of 30, 43.3%) and non-Hodgkin's lymphoma (NHL) (2 of 5, 40%) cases from HIV-seronegative patients and in HIV-related, EBV+ NHLs (4 of 7, 57.1%). Conversely, a 30-bp LMP-1 deletion was found in 10 of 12 HIV-associated HD cases (83%), a prevalence significantly higher than that detected in HIV-unrelated HD (P = .01). These findings indicate that: (1) the same EBV strain carrying LMP-1 deletions is harbored by normal and neoplastic cells of patients with EBV+ disorders, ruling out that these mutations might result from immunoselection phenomena; (2) in the Italian population, the prevalence of LMP-1 deletion mutants is comparable to that of EBV strains with full-length LMP-1; (3) HIV-induced immunosuppression is not associated with an increased prevalence of LMP-1 deletions in PBMCs; and (4) HIV-related HD cases, but not those of HIV-seronegative Italian patients, are closely correlated with the presence of LMP-1 deletions, suggesting that infection with these strains may increase the risk of developing HD in the HIV setting.
研究了6例爱泼斯坦-巴尔病毒(EBV)相关的淋巴增殖性疾病,以验证肿瘤细胞所携带的EBV毒株是否与同一患者正常淋巴细胞所携带病毒具有相同的EBNA-2和潜伏膜蛋白-1(LMP-1)DNA序列。在每个病例中,对肿瘤淋巴结、反应性淋巴结病和/或EBV阳性自发淋巴母细胞系的分析在型特异性EBNA-2区域和LMP-1基因方面给出了一致的结果。特别是,5例病例在正常细胞和肿瘤细胞的LMP-1基因3'端均显示相同的缺失。我们还测定了来自意大利人的大量正常外周血单核细胞(PBMC)中LMP-1缺失的发生率。分析表明,来自人类免疫缺陷病毒(HIV)血清阴性供体的PBMC中有50%(18例中的9例)在LMP-1基因的C端部分存在30 bp的缺失,而在约44%(18例中的8例)的病例中扩增出未缺失的片段。仅1个样本(5.6%)显示全长LMP-1条带与缺失片段一起扩增。同样,来自HIV感染患者的PBMC中全长LMP-1片段(37例中的17例,46%)和缺失片段(37例中的16例,43.2%)的发生率几乎相同,而约11%的样本(37例中的4例)显示双重感染的证据。值得注意的是,在来自HIV血清阴性患者的EBV阳性霍奇金淋巴瘤(HD)(30例中的13例,43.3%)和非霍奇金淋巴瘤(NHL)(5例中的2例,40%)病例以及HIV相关的EBV阳性NHL(7例中的4例,57.1%)中,检测到LMP-1基因缺失的发生率相似。相反,在12例HIV相关HD病例中的10例(83%)发现了30 bp的LMP-1缺失,其发生率显著高于在与HIV无关的HD中检测到的发生率(P = 0.01)。这些发现表明:(1)EBV阳性疾病患者的正常细胞和肿瘤细胞携带相同的带有LMP-1缺失的EBV毒株,排除了这些突变可能由免疫选择现象导致的可能性;(2)在意大利人群中,LMP-1缺失突变体的发生率与具有全长LMP-1的EBV毒株的发生率相当;(3)HIV诱导的免疫抑制与PBMC中LMP-1缺失发生率的增加无关;(4)HIV相关HD病例,而非HIV血清阴性的意大利患者的HD病例,与LMP-1缺失的存在密切相关,表明感染这些毒株可能增加HIV感染情况下发生HD的风险。